APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation
檔案
本條目沒有附加檔案。
日期
2019-11-01
作者
類型
系所
期刊名稱
HEPATOLOGY INTERNATIONAL
卷期與頁次
第 13 卷第 6 期,頁 649–661
ISSN
1936-0533
語言
英文
摘要
In the direct-acting antiviral (DAA) era for hepatitis C virus (HCV) infection, sustained virological response (SVR) is very high, but close attention must be paid to the possible occurrence of hepatocellular carcinoma (HCC) and reactivation of hepatitis B virus (HBV) in patients with co-infection who achieved SVR in short term. HCC occurrence was more often observed in patients with previous HCC history. We found occurrence of HCC in 178 (29.6%) of 602 patients with previous HCC history (15.4 months mean follow-up post-DAA initiation) but, in contrast, in only 604 (1.3%) of 45,870 patients without previous HCC history (18.2 months mean follow-up). Thus, in these guidelines, we recommend the following: in patients with previous HCC history, surveillance at 4-month intervals for HCC by ultrasonography (US) and tumor markers should be performed. In patients without previous HCC history, surveillance at 6- to 12-month intervals for HCC including US is recommended until the long-term DAA treatment effects, especially for the resolution of liver fibrosis, are confirmed. This guideline also includes recommendations on how to follow-up patients who have been infected with both HCV and HBV. When HCV was eradicated in these HBsAg-positive patients or patients with previous HBV infection ( anti-HBc and/ or anti-HBs-positive), it was shown that HBV reactivation or HBV DNA reappearance was observed in 67 (41.4%) of 162 or 12 (0.9%) of 1317, respectively. For these co-infected patients, careful attention should be paid to HBV reactivation for 24 weeks post-treatment.
所屬典藏
期刊論文引用此條目
Kanda, T., Lau, G. K. K., Wei, L., Moriyama, M., Yu, M.-L., Chuang, W.-L., Ibrahim, A., Lesmana, C. R. A., Sollano, J., Kumar, M., Jindal, A., Sharma, B. C., Hamid, S. S., Dokmeci, A. K., Mamun-Al-Mahtab, McCaughan, G. W., Wasim, J., Crawford, D. H. G., Kao, J.-H., … Omata, M. (2019). APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. HEPATOLOGY INTERNATIONAL, 13(6), 649–661. https://doi.org/10.1007/s12072-019-09988-7
引用文字依 APA 第 7 版格式自動產生,使用前請再核對。
分享
永久網址:https://ir.lib.nycu.edu.tw/handle/11536/153411